In this Buffalo Rising guest commentary, Scott Mazza, founder of Vitality CBD, analyzes Buffalo’s path from cannabis legalization to its first recreational dispensary opening, highlighting regulatory delays and the uneven rollout of retail licenses in Western New York. Drawing on his perspective as a license applicant, he details how court challenges, CAURD licensing rules, and state-level pauses have shaped the local market while expanding opportunities remain uncertain. The article situates Buffalo at a pivotal moment, examining the tension between regulated, gray, and unregulated cannabis markets and outlining what these dynamics mean for the city’s economic and cultural future.

In this National CBD Day feature, consumer journalist Trae Bodge highlights a range of topical CBD products she personally tested, including Vitality CBD salves, which she describes as organic, lab-tested formulations designed for pain relief, tension, and relaxation. Vitality CBD is presented alongside other wellness brands within a broader lifestyle and shopping context, with specific attention to formulation strength, ingredients, and sensory experience. The article positions Vitality CBD as a practical, everyday option within the topical CBD category, evaluated through hands-on consumer use rather than clinical claims.

In this industry analysis published by Nutritional Outlook, Scott Mazza, co-founder and COO of Vitality CBD, explains why delta-8 THC has become one of the most contested compounds in the hemp market, outlining its chemistry, production from hemp-derived CBD, and reported consumer effects. He examines the regulatory gray area created by the 2018 Farm Bill, contrasting federal legality with increasing state-level restrictions and FDA warnings tied to product safety and unsubstantiated claims. The article argues for clearer legislation, stronger quality standards, and expanded research to resolve uncertainty around delta-8 THC and protect both consumers and the broader hemp industry.

This The Bluntness feature by Scott Mazza, co-founder and COO of Vitality CBD, explores how terpenes shape flavor, effects, and therapeutic outcomes beyond THC alone. Citing peer-reviewed research, Mazza explains how specific terpene–cannabinoid combinations (“chemovars”) are linked to differing levels of symptom relief for conditions such as pain, anxiety, and depression. He argues that moving away from marketing-driven strain names toward chemical profiling is critical for advancing medical credibility, consumer transparency, and evidence-based cannabis use.

In this guest analysis, Scott Mazza, co-founder and COO of Vitality CBD, examines emerging clinical evidence on cannabidiol (CBD) as a sleep aid, contextualizing it against widespread sleep disorders in the U.S. He reviews a large peer-reviewed study showing that low doses of CBD can improve sleep quality with a favorable safety profile, performing comparably to melatonin, and without added benefit from minor cannabinoids. The article emphasizes both the promise and the limits of current evidence, underscoring the importance of product quality, third-party testing, and realistic expectations when considering CBD for sleep.

In this Buffalo News report on proposed changes to New York’s cannabis regulations, Scott Mazza, co-founder and COO of Vitality CBD, warns that allowing large, out-of-state medical marijuana operators to enter the adult-use market early would undermine small and emerging local businesses. Mazza frames the policy shift as a reversal of earlier state commitments meant to give farmers, social-equity licensees, and independent operators time to establish themselves before facing corporate competition. His comments situate the issue as one of regulatory fairness, market integrity, and long-term sustainability for New York’s cannabis industry.

In this NY Cannabis Insider guest column, Scott Mazza, co-founder and COO of Vitality CBD, examines Google’s 2023 policy shift allowing limited advertising for compliant, hemp-derived CBD products. He explains how certification requirements, age and geography restrictions, and third-party testing create new, but highly regulated, digital marketing pathways, while also reinforcing quality and consumer protection standards. Mazza positions the change as a meaningful step toward legitimizing the CBD industry and reshaping public perception through responsible, transparent advertising.

In this Nutritional Outlook article, Scott Mazza, co-founder and COO of Vitality CBD, argues that the 2023 Farm Bill must resolve ongoing regulatory ambiguity around CBD in foods, beverages, and dietary supplements. He outlines how the lack of clear FDA pathways has led to widespread issues with product purity, potency, labeling accuracy, and consumer safety, citing data on contamination and mislabeling across the market. Mazza calls for defined federal standards and enforcement, particularly around supplements and emerging cannabinoids like delta-8 THC, to protect consumers while providing long-term regulatory certainty for responsible producers.

In this analysis, Scott Mazza of Vitality CBD reviews recent peer-reviewed studies suggesting CBD may reduce opioid reward, support pain management, and enhance the effectiveness of naloxone in overdose response. He emphasizes that while these findings point to meaningful medical potential, widespread mislabeling, contamination, and lack of regulatory oversight currently undermine safe clinical use. The article argues that FDA guidance, medical-grade production standards, and routine third-party testing are essential for CBD to play a credible role in addressing the opioid crisis.

In this guest column, Scott Mazza of Vitality CBD examines emerging peer-reviewed research suggesting that cannabidiol may help reduce opioid reward, alleviate pain, and enhance the effectiveness of naloxone in overdose response. Mazza argues that these findings position CBD as a potentially valuable adjunct in addressing the opioid crisis, but only if products meet medical-grade standards for purity, potency, and consistency. The article stresses that meaningful clinical application will depend on stricter regulation, independent testing, and the elimination of low-quality products that currently undermine safety and credibility.

In this policy-focused opinion piece, Scott Mazza of Vitality CBD examines how court-ordered injunctions and regulatory uncertainty have stalled New York’s adult-use cannabis retail rollout, leaving qualified applicants in limbo. Drawing on firsthand experience pursuing a retail license in an affected region, Mazza outlines the consequences of delayed guidance, uneven enforcement against gray-market operators, and mounting legal costs. The article argues that clearer timelines, transparency around standard licensing, and stronger action against illicit sales are essential to restoring fairness and stability in New York’s legal cannabis market.

In this firsthand product review, She Scribes explores consumer perceptions of hemp-derived CBD through personal testing of multiple offerings from Vitality CBD, including full-spectrum oils and topical salves. The article emphasizes common themes in the CBD market, such as variability in individual response, the importance of product quality, and third-party testing, while candidly documenting mixed results across pain relief, relaxation, and post-surgery recovery. Positioned as a lifestyle and wellness perspective rather than a clinical evaluation, the piece reflects how everyday consumers navigate CBD amid broad claims and uneven industry standards.